A high efficient FVIII variant corrects bleeding in hemophilia A mouse model

Area of Science:

• Biochemistry
• Gene Therapy
• Hematology

Background:

• Hemophilia A is a bleeding disorder due to Factor VIII (FVIII) deficiency.
• Low FVIII expression and mRNA instability hinder gene therapy for hemophilia A.
• Site-directed mutagenesis can improve FVIII protein expression.

Purpose of the Study:

• To investigate the impact of a specific point mutation (P290T) on B-domain-deleted FVIII (BDD-FVIII) activity.
• To evaluate the efficacy of gene delivery using the P290T variant in a mouse model of hemophilia A.

Main Methods:

• Site-directed mutagenesis was used to introduce the P290T mutation into BDD-FVIII cDNA.
• Hydrodynamic gene delivery of P290T cDNA was performed in FVIII-deficient mice.
• In vitro activity assays, bleeding time measurements, blood loss quantification, and histological analyses were conducted.

Main Results:

• The P290T mutation enhanced the in vitro specific activity of BDD-FVIII.
• Gene delivery of P290T cDNA corrected bleeding symptoms in FVIII-deficient mice.
• High plasma FVIII coagulant activity and reduced bleeding were observed in mice treated with P290T variant, with no signs of liver damage or toxicity.

Conclusions:

• The P290T mutation significantly increases both in vitro and in vivo FVIII coagulant activity.
• This variant shows potential for developing more effective gene replacement therapies for hemophilia A.
• The P290T mutation represents a promising strategy to overcome challenges in hemophilia A gene therapy.